Home Healthcare Medical Devices Hemoglobinopathies Market

Hemoglobinopathies Market Size, Share & Trends Analysis Report By Type (Thalassemia, Sickle Cell Disease, Hemoglobin C disease, Hemoglobin E disease, Others), By Treatment Type (Blood Transfusion, Gene Therapy, Stem Cell Transplant, Pharmacotherapy, Others), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: September 22, 2025 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Hemoglobinopathies Market, By Type 2022-2034 (USD MILLION/ Units)
    1. Thalassemia
    2. Sickle Cell Disease
    3. Hemoglobin C disease
    4. Hemoglobin E disease
    5. Others
  2. Hemoglobinopathies Market, By Treatment Type 2022-2034 (USD MILLION/ Units)
    1. Blood Transfusion
    2. Gene Therapy
    3. Stem Cell Transplant
    4. Pharmacotherapy
    5. Others
  3. Hemoglobinopathies Market, By End User 2022-2034 (USD MILLION/ Units)
    1. Hospitals
    2. Specialty Clinics
    3. Ambulatory Surgical Centers
    4. Others
  4. Regional Hemoglobinopathies Market
    1. North America
      1. North America Hemoglobinopathies Market By Type 2022-2034 (USD MILLION/ Units)
        1. Thalassemia
        2. Sickle Cell Disease
        3. Hemoglobin C disease
        4. Hemoglobin E disease
        5. Others
      2. North America Hemoglobinopathies Market By Treatment Type 2022-2034 (USD MILLION/ Units)
        1. Blood Transfusion
        2. Gene Therapy
        3. Stem Cell Transplant
        4. Pharmacotherapy
        5. Others
      3. North America Hemoglobinopathies Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Specialty Clinics
        3. Ambulatory Surgical Centers
        4. Others
      4. U.S.
        1. Thalassemia
        2. Sickle Cell Disease
        3. Hemoglobin C disease
        4. Hemoglobin E disease
        5. Others
        6. Blood Transfusion
        7. Gene Therapy
        8. Stem Cell Transplant
        9. Pharmacotherapy
        10. Others
        11. Hospitals
        12. Specialty Clinics
        13. Ambulatory Surgical Centers
        14. Others
      5. Canada
        1. Thalassemia
        2. Sickle Cell Disease
        3. Hemoglobin C disease
        4. Hemoglobin E disease
        5. Others
        6. Blood Transfusion
        7. Gene Therapy
        8. Stem Cell Transplant
        9. Pharmacotherapy
        10. Others
        11. Hospitals
        12. Specialty Clinics
        13. Ambulatory Surgical Centers
        14. Others
    2. Europe
      1. Europe Hemoglobinopathies Market By Type 2022-2034 (USD MILLION/ Units)
        1. Thalassemia
        2. Sickle Cell Disease
        3. Hemoglobin C disease
        4. Hemoglobin E disease
        5. Others
      2. Europe Hemoglobinopathies Market By Treatment Type 2022-2034 (USD MILLION/ Units)
        1. Blood Transfusion
        2. Gene Therapy
        3. Stem Cell Transplant
        4. Pharmacotherapy
        5. Others
      3. Europe Hemoglobinopathies Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Specialty Clinics
        3. Ambulatory Surgical Centers
        4. Others
      4. U.K.
        1. Thalassemia
        2. Sickle Cell Disease
        3. Hemoglobin C disease
        4. Hemoglobin E disease
        5. Others
        6. Blood Transfusion
        7. Gene Therapy
        8. Stem Cell Transplant
        9. Pharmacotherapy
        10. Others
        11. Hospitals
        12. Specialty Clinics
        13. Ambulatory Surgical Centers
        14. Others
      5. Germany
        1. Thalassemia
        2. Sickle Cell Disease
        3. Hemoglobin C disease
        4. Hemoglobin E disease
        5. Others
        6. Blood Transfusion
        7. Gene Therapy
        8. Stem Cell Transplant
        9. Pharmacotherapy
        10. Others
        11. Hospitals
        12. Specialty Clinics
        13. Ambulatory Surgical Centers
        14. Others
      6. France
        1. Thalassemia
        2. Sickle Cell Disease
        3. Hemoglobin C disease
        4. Hemoglobin E disease
        5. Others
        6. Blood Transfusion
        7. Gene Therapy
        8. Stem Cell Transplant
        9. Pharmacotherapy
        10. Others
        11. Hospitals
        12. Specialty Clinics
        13. Ambulatory Surgical Centers
        14. Others
      7. Spain
        1. Thalassemia
        2. Sickle Cell Disease
        3. Hemoglobin C disease
        4. Hemoglobin E disease
        5. Others
        6. Blood Transfusion
        7. Gene Therapy
        8. Stem Cell Transplant
        9. Pharmacotherapy
        10. Others
        11. Hospitals
        12. Specialty Clinics
        13. Ambulatory Surgical Centers
        14. Others
      8. Italy
        1. Thalassemia
        2. Sickle Cell Disease
        3. Hemoglobin C disease
        4. Hemoglobin E disease
        5. Others
        6. Blood Transfusion
        7. Gene Therapy
        8. Stem Cell Transplant
        9. Pharmacotherapy
        10. Others
        11. Hospitals
        12. Specialty Clinics
        13. Ambulatory Surgical Centers
        14. Others
      9. Russia
        1. Thalassemia
        2. Sickle Cell Disease
        3. Hemoglobin C disease
        4. Hemoglobin E disease
        5. Others
        6. Blood Transfusion
        7. Gene Therapy
        8. Stem Cell Transplant
        9. Pharmacotherapy
        10. Others
        11. Hospitals
        12. Specialty Clinics
        13. Ambulatory Surgical Centers
        14. Others
      10. Nordic
        1. Thalassemia
        2. Sickle Cell Disease
        3. Hemoglobin C disease
        4. Hemoglobin E disease
        5. Others
        6. Blood Transfusion
        7. Gene Therapy
        8. Stem Cell Transplant
        9. Pharmacotherapy
        10. Others
        11. Hospitals
        12. Specialty Clinics
        13. Ambulatory Surgical Centers
        14. Others
      11. Benelux
        1. Thalassemia
        2. Sickle Cell Disease
        3. Hemoglobin C disease
        4. Hemoglobin E disease
        5. Others
        6. Blood Transfusion
        7. Gene Therapy
        8. Stem Cell Transplant
        9. Pharmacotherapy
        10. Others
        11. Hospitals
        12. Specialty Clinics
        13. Ambulatory Surgical Centers
        14. Others
      12. Rest of Europe
        1. Thalassemia
        2. Sickle Cell Disease
        3. Hemoglobin C disease
        4. Hemoglobin E disease
        5. Others
        6. Blood Transfusion
        7. Gene Therapy
        8. Stem Cell Transplant
        9. Pharmacotherapy
        10. Others
        11. Hospitals
        12. Specialty Clinics
        13. Ambulatory Surgical Centers
        14. Others
    3. APAC
      1. APAC Hemoglobinopathies Market By Type 2022-2034 (USD MILLION/ Units)
        1. Thalassemia
        2. Sickle Cell Disease
        3. Hemoglobin C disease
        4. Hemoglobin E disease
        5. Others
      2. APAC Hemoglobinopathies Market By Treatment Type 2022-2034 (USD MILLION/ Units)
        1. Blood Transfusion
        2. Gene Therapy
        3. Stem Cell Transplant
        4. Pharmacotherapy
        5. Others
      3. APAC Hemoglobinopathies Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Specialty Clinics
        3. Ambulatory Surgical Centers
        4. Others
      4. China
        1. Thalassemia
        2. Sickle Cell Disease
        3. Hemoglobin C disease
        4. Hemoglobin E disease
        5. Others
        6. Blood Transfusion
        7. Gene Therapy
        8. Stem Cell Transplant
        9. Pharmacotherapy
        10. Others
        11. Hospitals
        12. Specialty Clinics
        13. Ambulatory Surgical Centers
        14. Others
      5. Korea
        1. Thalassemia
        2. Sickle Cell Disease
        3. Hemoglobin C disease
        4. Hemoglobin E disease
        5. Others
        6. Blood Transfusion
        7. Gene Therapy
        8. Stem Cell Transplant
        9. Pharmacotherapy
        10. Others
        11. Hospitals
        12. Specialty Clinics
        13. Ambulatory Surgical Centers
        14. Others
      6. Japan
        1. Thalassemia
        2. Sickle Cell Disease
        3. Hemoglobin C disease
        4. Hemoglobin E disease
        5. Others
        6. Blood Transfusion
        7. Gene Therapy
        8. Stem Cell Transplant
        9. Pharmacotherapy
        10. Others
        11. Hospitals
        12. Specialty Clinics
        13. Ambulatory Surgical Centers
        14. Others
      7. India
        1. Thalassemia
        2. Sickle Cell Disease
        3. Hemoglobin C disease
        4. Hemoglobin E disease
        5. Others
        6. Blood Transfusion
        7. Gene Therapy
        8. Stem Cell Transplant
        9. Pharmacotherapy
        10. Others
        11. Hospitals
        12. Specialty Clinics
        13. Ambulatory Surgical Centers
        14. Others
      8. Australia
        1. Thalassemia
        2. Sickle Cell Disease
        3. Hemoglobin C disease
        4. Hemoglobin E disease
        5. Others
        6. Blood Transfusion
        7. Gene Therapy
        8. Stem Cell Transplant
        9. Pharmacotherapy
        10. Others
        11. Hospitals
        12. Specialty Clinics
        13. Ambulatory Surgical Centers
        14. Others
      9. Taiwan
        1. Thalassemia
        2. Sickle Cell Disease
        3. Hemoglobin C disease
        4. Hemoglobin E disease
        5. Others
        6. Blood Transfusion
        7. Gene Therapy
        8. Stem Cell Transplant
        9. Pharmacotherapy
        10. Others
        11. Hospitals
        12. Specialty Clinics
        13. Ambulatory Surgical Centers
        14. Others
      10. South East Asia
        1. Thalassemia
        2. Sickle Cell Disease
        3. Hemoglobin C disease
        4. Hemoglobin E disease
        5. Others
        6. Blood Transfusion
        7. Gene Therapy
        8. Stem Cell Transplant
        9. Pharmacotherapy
        10. Others
        11. Hospitals
        12. Specialty Clinics
        13. Ambulatory Surgical Centers
        14. Others
      11. Rest of Asia-Pacific
        1. Thalassemia
        2. Sickle Cell Disease
        3. Hemoglobin C disease
        4. Hemoglobin E disease
        5. Others
        6. Blood Transfusion
        7. Gene Therapy
        8. Stem Cell Transplant
        9. Pharmacotherapy
        10. Others
        11. Hospitals
        12. Specialty Clinics
        13. Ambulatory Surgical Centers
        14. Others
    4. Middle East and Africa
      1. Middle East and Africa Hemoglobinopathies Market By Type 2022-2034 (USD MILLION/ Units)
        1. Thalassemia
        2. Sickle Cell Disease
        3. Hemoglobin C disease
        4. Hemoglobin E disease
        5. Others
      2. Middle East and Africa Hemoglobinopathies Market By Treatment Type 2022-2034 (USD MILLION/ Units)
        1. Blood Transfusion
        2. Gene Therapy
        3. Stem Cell Transplant
        4. Pharmacotherapy
        5. Others
      3. Middle East and Africa Hemoglobinopathies Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Specialty Clinics
        3. Ambulatory Surgical Centers
        4. Others
      4. UAE
        1. Thalassemia
        2. Sickle Cell Disease
        3. Hemoglobin C disease
        4. Hemoglobin E disease
        5. Others
        6. Blood Transfusion
        7. Gene Therapy
        8. Stem Cell Transplant
        9. Pharmacotherapy
        10. Others
        11. Hospitals
        12. Specialty Clinics
        13. Ambulatory Surgical Centers
        14. Others
      5. Turkey
        1. Thalassemia
        2. Sickle Cell Disease
        3. Hemoglobin C disease
        4. Hemoglobin E disease
        5. Others
        6. Blood Transfusion
        7. Gene Therapy
        8. Stem Cell Transplant
        9. Pharmacotherapy
        10. Others
        11. Hospitals
        12. Specialty Clinics
        13. Ambulatory Surgical Centers
        14. Others
      6. Saudi Arabia
        1. Thalassemia
        2. Sickle Cell Disease
        3. Hemoglobin C disease
        4. Hemoglobin E disease
        5. Others
        6. Blood Transfusion
        7. Gene Therapy
        8. Stem Cell Transplant
        9. Pharmacotherapy
        10. Others
        11. Hospitals
        12. Specialty Clinics
        13. Ambulatory Surgical Centers
        14. Others
      7. South Africa
        1. Thalassemia
        2. Sickle Cell Disease
        3. Hemoglobin C disease
        4. Hemoglobin E disease
        5. Others
        6. Blood Transfusion
        7. Gene Therapy
        8. Stem Cell Transplant
        9. Pharmacotherapy
        10. Others
        11. Hospitals
        12. Specialty Clinics
        13. Ambulatory Surgical Centers
        14. Others
      8. Egypt
        1. Thalassemia
        2. Sickle Cell Disease
        3. Hemoglobin C disease
        4. Hemoglobin E disease
        5. Others
        6. Blood Transfusion
        7. Gene Therapy
        8. Stem Cell Transplant
        9. Pharmacotherapy
        10. Others
        11. Hospitals
        12. Specialty Clinics
        13. Ambulatory Surgical Centers
        14. Others
      9. Nigeria
        1. Thalassemia
        2. Sickle Cell Disease
        3. Hemoglobin C disease
        4. Hemoglobin E disease
        5. Others
        6. Blood Transfusion
        7. Gene Therapy
        8. Stem Cell Transplant
        9. Pharmacotherapy
        10. Others
        11. Hospitals
        12. Specialty Clinics
        13. Ambulatory Surgical Centers
        14. Others
      10. Rest of MEA
        1. Thalassemia
        2. Sickle Cell Disease
        3. Hemoglobin C disease
        4. Hemoglobin E disease
        5. Others
        6. Blood Transfusion
        7. Gene Therapy
        8. Stem Cell Transplant
        9. Pharmacotherapy
        10. Others
        11. Hospitals
        12. Specialty Clinics
        13. Ambulatory Surgical Centers
        14. Others
    5. LATAM
      1. LATAM Hemoglobinopathies Market By Type 2022-2034 (USD MILLION/ Units)
        1. Thalassemia
        2. Sickle Cell Disease
        3. Hemoglobin C disease
        4. Hemoglobin E disease
        5. Others
      2. LATAM Hemoglobinopathies Market By Treatment Type 2022-2034 (USD MILLION/ Units)
        1. Blood Transfusion
        2. Gene Therapy
        3. Stem Cell Transplant
        4. Pharmacotherapy
        5. Others
      3. LATAM Hemoglobinopathies Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Specialty Clinics
        3. Ambulatory Surgical Centers
        4. Others
      4. Brazil
        1. Thalassemia
        2. Sickle Cell Disease
        3. Hemoglobin C disease
        4. Hemoglobin E disease
        5. Others
        6. Blood Transfusion
        7. Gene Therapy
        8. Stem Cell Transplant
        9. Pharmacotherapy
        10. Others
        11. Hospitals
        12. Specialty Clinics
        13. Ambulatory Surgical Centers
        14. Others
      5. Mexico
        1. Thalassemia
        2. Sickle Cell Disease
        3. Hemoglobin C disease
        4. Hemoglobin E disease
        5. Others
        6. Blood Transfusion
        7. Gene Therapy
        8. Stem Cell Transplant
        9. Pharmacotherapy
        10. Others
        11. Hospitals
        12. Specialty Clinics
        13. Ambulatory Surgical Centers
        14. Others
      6. Argentina
        1. Thalassemia
        2. Sickle Cell Disease
        3. Hemoglobin C disease
        4. Hemoglobin E disease
        5. Others
        6. Blood Transfusion
        7. Gene Therapy
        8. Stem Cell Transplant
        9. Pharmacotherapy
        10. Others
        11. Hospitals
        12. Specialty Clinics
        13. Ambulatory Surgical Centers
        14. Others
      7. Chile
        1. Thalassemia
        2. Sickle Cell Disease
        3. Hemoglobin C disease
        4. Hemoglobin E disease
        5. Others
        6. Blood Transfusion
        7. Gene Therapy
        8. Stem Cell Transplant
        9. Pharmacotherapy
        10. Others
        11. Hospitals
        12. Specialty Clinics
        13. Ambulatory Surgical Centers
        14. Others
      8. Colombia
        1. Thalassemia
        2. Sickle Cell Disease
        3. Hemoglobin C disease
        4. Hemoglobin E disease
        5. Others
        6. Blood Transfusion
        7. Gene Therapy
        8. Stem Cell Transplant
        9. Pharmacotherapy
        10. Others
        11. Hospitals
        12. Specialty Clinics
        13. Ambulatory Surgical Centers
        14. Others
      9. Rest of LATAM
        1. Thalassemia
        2. Sickle Cell Disease
        3. Hemoglobin C disease
        4. Hemoglobin E disease
        5. Others
        6. Blood Transfusion
        7. Gene Therapy
        8. Stem Cell Transplant
        9. Pharmacotherapy
        10. Others
        11. Hospitals
        12. Specialty Clinics
        13. Ambulatory Surgical Centers
        14. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.